Full-Time
Lab Assistant
Manufacturing
Arrowhead Pharmaceuticals
501-1,000 employees
Develops RNAi-based gene-silencing therapies
Compensation Overview
$40k - $45k/yr
Fitchburg, WI, USA
In Person
 Biology & Biotech (1) |
|---|
Get referred to Arrowhead Pharmaceuticals
See people who can refer or advise you
- High school diploma
- Good verbal and written communication skills
- Ability to work in a team environment
- Ability to pay attention to detail
- Maintain glassware for the laboratory
- Maintain cleanliness and orderliness of work areas
- Maintain stocks of laboratory supplies and material and maintains appropriate records
- Follow safety procedures for chemical handling, as appropriate
- Follow batch records, SOPS, and work instructions to detail
- Document all operations in batch records and notebooks
- Comply with GMP protocols
- Assist with and support operation of large scale oligonucleotide manufacturing equipment (i.e. oligonucleotide synthesizer, purification skid, tangential flow filtration system, lyophilizer, ChemGlass reactors, pH/conductivity meters, peristaltic pumps, etc.)
- Previous experience in a laboratory setting
- Some college or concurrent college course attendance
Arrowhead Pharmaceuticals develops medicines using RNA interference (RNAi) to silence disease-causing genes. The company’s approach uses a library of RNA chemistries and delivery methods to trigger RNAi, enabling rapid and durable reduction of target gene expression in cells. This gene-silencing strategy aims to treat severe genetic diseases such as cystic fibrosis and hepatitis B by lowering disease-related proteins. Arrowhead’s products are advanced through discovery and development partnerships, licensing deals, and potential commercialization of approved therapies. The company differentiates itself through a broad RNAi platform, proprietary delivery tech, and collaborations with larger pharma firms to advance its pipeline. Its goal is to provide new treatment options for conditions with limited or no effective therapies by translating gene silencing into medicines that can halt or reverse disease progression.
Company Size
501-1,000
Company Stage
IPO
Headquarters
Pasadena, California
Founded
2004
Get referred to Arrowhead Pharmaceuticals
See people who can refer or advise you
Simplify's Take
What believers are saying
- August 4, 2026 SHASTA-3 and SHASTA-4 cut triglycerides 79% and 81%.
- Pooled SHASTA data cut acute pancreatitis events 78%, with 100% reduction in highest-risk patients.
- REDEMPLO revenue reached $2.4 million quarterly, and approvals now span five geographies.
What critics are saying
- Ionis sued Arrowhead over plozasiran patents in California; an injunction would cripple sales.
- Third-quarter operating expenses hit $245 million while REDEMPLO generated only $2.4 million.
- Most of Arrowhead's 23 clinical candidates remain early-stage; one failure can erase valuation.
What makes Arrowhead Pharmaceuticals unique
- TRiM delivery reaches liver, lung, muscle, adipose, and CNS from one RNAi platform.
- REDEMPLO makes Arrowhead a commercial-stage RNAi company, not just a development story.
- Madrigal's May 2026 $1 billion ARO-PNPLA3 license validates Arrowhead's metabolic genetics franchise.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
Paid Vacation
Paid Sick Leave
Growth & Insights and Company News
6 month growth
↑ 35%1 year growth
↑ 35%2 year growth
↑ 34%Arrowhead Pharmaceuticals reported positive Phase III results for plozasiran in severe hypertriglyceridemia, showing triglyceride reductions of 79% to 81% and a 78% decrease in acute pancreatitis events versus placebo. The company plans to submit a supplemental FDA application before the end of 2026. The firm's REDEMPLO therapy for familial chylomicronemia syndrome is gaining traction, with prescription volume more than doubling and quarterly revenue reaching approximately $2.4 million. Over 400 prescribers are now supported. For the fiscal third quarter ended 30 June 2026, Arrowhead recorded revenue of approximately $75 million, up from $28 million year-on-year. Net loss widened to $194.3 million from $175.2 million. The company held about $1.6 billion in cash and investments.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) announces quarterly earnings results. August 4, 2026 Key points. * Arrowhead missed on earnings but beat revenue expectations: The company reported a quarterly loss of $1.36 per share versus the $1.23 consensus estimate, while revenue reached $75.25 million, up 171% year over year and well above expectations. * Clinical and commercial progress provided key catalysts: Phase III SHASTA-3 and SHASTA-4 met their primary and secondary endpoints, while REDEMPLO prescriptions more than doubled sequentially and generated approximately $2.4 million in quarterly revenue. * Losses and spending continued to widen: Net loss increased to $194.3 million and operating expenses rose to about $245 million, although Arrowhead ended the period with roughly $1.6 billion in cash and investments. Analysts maintained a generally positive outlook, with a consensus "Moderate Buy" rating and a $96.92 price target. * Five stocks we like better than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) released its quarterly earnings results on Tuesday. The biotechnology company reported ($1.36) earnings per share for the quarter, missing the consensus estimate of ($1.23) by ($0.13), FiscalAI reports. The company had revenue of $75.25 million during the quarter, compared to the consensus estimate of $44.17 million. Arrowhead Pharmaceuticals had a negative net margin of 48.38% and a negative return on equity of 55.09%. The firm's revenue was up 171.0% compared to the same quarter last year. During the same period in the prior year, the company earned ($1.26) earnings per share. Here are the key takeaways from Arrowhead Pharmaceuticals' conference call: * Phase III SHASTA-3 and SHASTA-4 both met all primary and prespecified secondary endpoints, with median triglyceride reductions of 79% and 81% and a 78% reduction in pooled acute pancreatitis events versus placebo. Arrowhead reported a 100% reduction in events among the highest-risk subgroup, though detailed data remain subject to the upcoming ESC presentation. * REDEMPLO's U.S. FCS launch continued to gain traction, with prescriptions more than doubling sequentially, over 400 unique prescribers, and approximately $2.4 million in quarterly commercial revenue. The company also reported approvals in Australia and the European Union, expanding its approved footprint to five geographies. * Arrowhead acquired a priority review voucher for $215 million, which it expects could shorten FDA review of the planned SHTG supplemental NDA from 10 months to six months. The company plans to submit the sNDA by the end of 2026 and is preparing to expand its field organization from about 5,000 to more than 20,000 healthcare-provider targets. * The pipeline has several potential catalysts, including September data for ARO-DIMER-PA and the ARO-MAPT CNS delivery program, plus fourth-quarter updates for ARO-INHBE and ARO-ALK7. Management expects 23 candidates in clinical trials by year-end, but most programs remain early-stage and carry substantial development risk. * Arrowhead's quarterly net loss widened to $194.3 million from $175.2 million year over year, while operating expenses rose to approximately $245 million as R&D and commercialization investments increased. The company held about $1.6 billion in cash and investments, but expects continued spending on clinical development, regulatory work, manufacturing, and potential SHTG launch preparation. Arrowhead Pharmaceuticals price performance. Shares of NASDAQ ARWR traded up $3.58 during midday trading on Tuesday, reaching $89.59. The company's stock had a trading volume of 2,031,077 shares, compared to its average volume of 2,464,807. The company has a debt-to-equity ratio of 1.41, a quick ratio of 6.23 and a current ratio of 6.23. The company has a market cap of $12.62 billion, a P/E ratio of -41.67 and a beta of 1.26. The business's 50 day moving average price is $79.26 and its two-hundred day moving average price is $70.85. Arrowhead Pharmaceuticals has a fifty-two week low of $15.01 and a fifty-two week high of $95.49. Analysts set new price targets. ARWR has been the topic of several research reports. Weiss Ratings downgraded Arrowhead Pharmaceuticals from a "hold (c-)" rating to a "sell (d-)" rating in a research report on Wednesday, May 20th. Sanford C. Bernstein lifted their price target on Arrowhead Pharmaceuticals from $35.00 to $46.00 and gave the stock a "market perform" rating in a report on Wednesday, May 13th. Stifel Nicolaus started coverage on Arrowhead Pharmaceuticals in a research note on Tuesday, July 14th. They issued a "buy" rating and a $98.00 price target for the company. Piper Sandler reaffirmed an "overweight" rating and issued a $126.00 price objective (up from $110.00) on shares of Arrowhead Pharmaceuticals in a report on Thursday, July 23rd. Finally, B. Riley Financial increased their price objective on Arrowhead Pharmaceuticals from $101.00 to $123.00 and gave the stock a "buy" rating in a research report on Thursday, July 30th. Nine equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $96.92. Discover more text messages AI Stocks Report Insider transactions at Arrowhead Pharmaceuticals. In related news, Director Hongbo Lu sold 2,970 shares of the stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $76.88, for a total transaction of $228,333.60. Following the sale, the director owned 52,012 shares of the company's stock, valued at $3,998,682.56. This represents a 5.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.60% of the stock is owned by corporate insiders. Institutional trading of Arrowhead Pharmaceuticals. A number of institutional investors have recently modified their holdings of the stock. Maryland State Retirement & Pension System lifted its position in Arrowhead Pharmaceuticals by 1.8% in the 4th quarter. Maryland State Retirement & Pension System now owns 20,241 shares of the biotechnology company's stock valued at $1,344,000 after acquiring an additional 365 shares in the last quarter. Corient Private Wealth LLC boosted its holdings in Arrowhead Pharmaceuticals by 3.1% in the 4th quarter. Corient Private Wealth LLC now owns 18,226 shares of the biotechnology company's stock worth $1,210,000 after buying an additional 551 shares during the period. Empowered Funds LLC grew its holdings in Arrowhead Pharmaceuticals by 4.5% during the 4th quarter. Empowered Funds LLC now owns 18,018 shares of the biotechnology company's stock valued at $1,196,000 after buying an additional 779 shares in the last quarter. Vanguard Personalized Indexing Management LLC boosted its holdings in Arrowhead Pharmaceuticals by 10.0% in the 4th quarter. Vanguard Personalized Indexing Management LLC now owns 9,154 shares of the biotechnology company's stock valued at $608,000 after purchasing an additional 829 shares during the period. Finally, iSAM Funds UK Ltd purchased a new position in Arrowhead Pharmaceuticals during the third quarter worth about $29,000. 62.61% of the stock is currently owned by institutional investors. Arrowhead Pharmaceuticals company profile. Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform - known internally as the Advanced RNAi Compound (ARC) technology - to silence disease-causing genes in patients suffering from genetically defined diseases. The company's approach aims to offer durable, targeted treatments across a range of therapeutic areas. The company's pipeline includes multiple candidates in various stages of development. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider Arrowhead Pharmaceuticals, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arrowhead Pharmaceuticals wasn't on the list. While Arrowhead Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Arrowhead Pharmaceuticals has transitioned from research-focused company to commercial enterprise with its first drug, REDEMPLO, now on the market. The company has written more than 400 prescriptions since launch, which management says exceeds initial expectations. The stock has surged over 500% in the past year, bringing market capitalisation to approximately $10.6 billion. It trades at a price-to-sales ratio of 17.1, significantly above the S&P 500's 3.3 multiple. The company remains unprofitable with an operating margin of -36%. Arrowhead announced today that its pivotal Phase 3 studies, SHASTA-3 and SHASTA-4, successfully met their primary endpoint for severe hypertriglyceridemia treatment. The company holds nearly $1.8 billion in cash and investments, with debt at 9.3% of market value.
The European Commission has authorised Arrowhead Pharmaceuticals' Redemplo (plozasiran) for treating adults with familial chylomicronemia syndrome (FCS), a rare genetic disorder causing severely elevated triglyceride levels. Redemplo, already approved in the US, is an apolipoprotein C III inhibitor. Phase III PALISADE study results showed Redemplo 25mg reduced median triglyceride levels by 80% at month 10. A pooled analysis across all doses demonstrated an 83% reduction in acute pancreatitis incidence. The approval does not require genetic confirmation of FCS, potentially broadening patient access. Redemplo will compete with other apoC-III inhibitors including Tryngolza and Waylivra, though its less-frequent dosing schedule may provide competitive advantage. Future expansion into broader hypertriglyceridemia populations is possible.
Tryngolza shows efficacy in severe hypertriglyceridemia as approval verdicts loom. This readout could boost Tryngolza's standing in its potential rivalry with Arrowhead's Redemplo in severe hypertriglyceridemia. Sobi has touted new efficacy results for Tryngolza (olezarsen) in severe hypertriglyceridemia, as the company and its commercial partner, Ionis Pharmaceuticals, gear up for the drug's potential launch in the indication. Through a pooled subgroup analysis, which factored in results from the Phase III CORE and CORE2 studies (NCT05079919; NCT05552326), Sobi found that patients with triglyceride levels of 10 mmol/L or more taking an 80mg, four-weekly dose of Tryngolza experienced a 66% placebo-adjusted drop in blood levels of the fatty acid at the six-month mark. Meanwhile, those on Tryngolza 50mg saw a 59% reduction. Overall, 85% of patients treated with Tryngolza achieved triglyceride levels lower than 10 mmol/L - a cutoff point in which the European Atherosclerosis Society (EAS) recommends that patients receive urgent, triglyceride-lowering treatment to diminish their risk of developing acute pancreatitis. Patients with blood triglyceride levels of 10 mmol/L or more are four times more likely to develop acute pancreatitis compared to patients with ideal blood concentrations. Sobi's chief medical officer, Lydia Abad-Franch, notes that the CORE findings highlight Tryngolza's potential as an "important part of a preventative approach to disease management in at-risk patients." These results, presented as a late-breaking abstract at the 2026 EAS congress, come as acute pancreatitis cases continue to burden healthcare systems worldwide. According to an epidemiological study published in BMC Gastroenterology, global cases saw a 59% uptick between 1990 and 2021, with deaths from the condition soaring 78.7% in this timeframe. Reinvigorating the severe hypertriglyceridemia market. Results of Sobi's pooled subgroup analysis come as the Swedish pharma company and the drug's original developer, Ionis, await the verdicts of US and European regulatory bodies on Tryngolza in severe hypertriglyceridemia, as the companies look to expand the drug's use to a broader patient population. The US Food and Drug Administration (FDA) has a target action date of 30 June. Ionis retains commercial rights to the drug in the US, while Sobi holds rights outside the US, apart from Canada and China. Neither company disclosed the financials of their partnership. Currently, Tryngolza is approved in both the US and European markets for the treatment of familial chylomicronaemia syndrome (FCS) - a rare genetic disorder driven by high blood triglyceride levels. However, Sobi and Ionis are not alone in their goal of breaking onto the severe hypertriglyceridemia market, as Arrowhead Pharmaceuticals is also running late-stage studies on its small interfering RNA (siRNA)-based triglyceride-lowering therapy, Redemplo (plozasiran). Like Tryngolza, Redemplo is approved in FCS. In a recent research note, Jefferies analysts praised Redemplo's recent launch in FCS, which they say was "trending better" versus Tryngolza at a similar timepoint - potentially indicating the future dynamics in the severe hypertriglyceridemia market. Currently, GlobalData predicts a blockbuster future for both Tryngolza and Redemplo, with consensus forecast estimating that the drugs will reach this status by 2029 and 2031, respectively. GlobalData is the parent company of Clinical Trials Arena.